WARWICK
CLINICAL TRIALS UNIT

Grants Co-ordinator

NIHR i4i Grant Programme

16 October 2025

**Letter of Support in Reference to Haem.io i4i Grant Application by Dr Luke Carter-Brzezinski**

To whom It may Concern

It is a privilege to write in support of the i4i Grant application by Dr Luke Carter-Brzezinski I write as Academic Director of one of the two largest bone marrow transplant and cellular therapy programmes in the UK, Chair of the UK Acute Myeloid Leukaemia Research Network, Lead of IMPACT- the UK's transplant trials cooperative, Chair of the UK Stem Cell Strategic Oversight Committee and Associate Editor of the Journal of Clinical Oncology-the world's most impactful oncology journal.

Haem.io is a novel diagnostic platform developed by a team of technical experts and senior NHS clinicians which I believe has the potential to transform diagnosis and decision making for patients with haematological malignancies across the NHS.  Having been introduced to the platform and its capabilities through demonstration and subsequent discussion at the recent UK AML Academy I, like many of my senior colleagues on the UK AML Research Network Steering Committee, have been hugely impressed by its to transform both the accuracy and speed of haematological malignancies, notably acute myeloid leukaemia and related disorders. The diagnosis of myeloid malignancies is becoming increasingly complex, driven by an ever-expanding list of critical genetic markers that dictate diagnosis, predict outcome, and increasingly direct treatment. This complex area is increasing difficult for clinicians to navigate and the levels of support and expertise in this area vary substantially. There is therefore a significant and growing need for intelligent tools that help clinicians to integrate this complex data accurately and efficiently, and which can therefore help ensure equitable access to the best possible care for all patients.

The Haem.io platform directly addresses this challenge. Its innovative approach, which uses intelligent software to assist clinicians extract data from complex reports and apply this to generate diagnosis, predict prognosis and provide supporting data to assist subsequent patient management in a transparent way. It has the clear potential to reduce diagnostic turnaround times, improve standardisation across the NHS, and ultimately, enhance patient care. The credibility of this project

Warwick Medical School
University of Warwick
Coventry, CV4 7AL.  UK
T +44 (0)24 76150925
www.warwick.ac.uk

is underpinned by its clinician-led approach, which combines deep technical expertise with the real-world clinical insights of practising haematologists. This ensures the tool is not just technically clever, but clinically relevant and built to solve the real-world problems we face in diagnostics and decision making.

I am convinced that the successful development of Haem.io has major implications for the haematology community and the broader NHS.  It is, I believe also scaleable to other major healthcare economises. To that end, the UK AML Research Network is committed to participate in a future pilot study to help validate the platform's clinical utility. I therefore offer my strongest support to the team and look forward to this important collaboration.

Yours sincerely,

C. F. Craddock

Prof Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, FMedSci
Professor of Haemato-oncology

www.warwick.ac.uk